lixisenatide: latest news - GoINPHARMA
Friday, 19 October 2018 - 14:40


Diabetes, Sanofi’s Soliqua 100/33 now available in the US

Sanofi announced that Soliqua™ (glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) is available in the US starting from today. The product is intended for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide….

CHMP gets OK for Sanofi’s fixed combination Lantus/lixisenatide

Sanofi has announced that EMA CHMP has adopted a positive opinion for the marketing authorization of Suliqua, the fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide. The Committee recommended the use of the product in combination with Metformin in…